专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明公开

US20240309100A1 Anti-Trkb Monoclonal Antibodies And Methods Of Use 审中-公开
公开(公告)号：US20240309100A1
公开(公告)日：2024-09-19
申请号：US18737782
申请日：2024-06-07
申请人： Regeneron Pharmaceuticals, Inc.
发明人： Susan D. Croll , Min Gao , Ying Hu
IPC分类号： C07K16/28 , A61K9/00 , A61K39/00 , A61P25/00
CPC分类号： C07K16/2863 , A61K9/0019 , A61P25/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides antibodies that bind specifically to TrkB and methods of using the same. According to certain embodiments, the antibodies of the invention are agonist antibodies that are neuroprotective, as shown by their effect on enhancing the survival of retinal ganglion cells in vitro. As such, these agonist antibodies may be used to treat diseases or disorders of the eye, such as, but not limited to glaucoma. In addition, other neuronal diseases or disorders may benefit from treatment with these agonist antibodies, including any disease or disorder characterized in part by neuronal damage. In certain embodiments, the invention includes antibodies that bind TrkB and mediate cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies.

12. 发明申请

US20200262901A1 ANTI-C5 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：US20200262901A1
公开(公告)日：2020-08-20
申请号：US16819989
申请日：2020-03-16
申请人： Regeneron Pharmaceuticals, Inc.
发明人： Ying Hu , Adrianna Latuszek , Carmelo Romano , William Olson
IPC分类号： C07K16/18 , A61K45/06 , A61K39/395
摘要： The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.

13. 发明授权

US10524458B2 Humanized C3 animals 有权
公开(公告)号：US10524458B2
公开(公告)日：2020-01-07
申请号：US16025377
申请日：2018-07-02
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： Ying Hu , Adrianna Latuszek , Jingtai Cao , Alexander Mujica , Stanley Wiegand , Andrew J. Murphy
IPC分类号： A01K67/027 , A61K49/00 , C07K14/47
摘要： Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus. Non-human animals comprising human or humanized C3 and/or C5 sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided.

14. 发明申请

US20150313194A1 HUMANIZED C5 AND C3 ANIMALS 有权
标题翻译：人造C5和C3动物
公开(公告)号：US20150313194A1
公开(公告)日：2015-11-05
申请号：US14703818
申请日：2015-05-04
申请人： Regeneron Pharmaceuticals, Inc.
发明人： Ying Hu , Adrianna Latuszek , Jingtai Cao , Alexander Mujica , Stanley Wiegand , John McWhirter , Andrew Murphy , Lynn Macdonald
IPC分类号： A01K67/027
CPC分类号： A01K67/0278 , A01K2207/15 , A01K2217/072 , A01K2227/105 , A01K2267/03 , A01K2267/0368 , A61K49/0008 , C07K14/472
摘要： Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus. Non-human animals comprising human or humanized C3 and/or C5 sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided.
摘要翻译：提供了包含人或人源化C3和/或C5核酸序列的非人动物以及使用其来鉴定能够调节补体系统的化合物的方法。描述了包含用人或人源化C5基因和/或C3基因替代内源性C5基因和/或C3基因的非人动物，以及用于制备和使用非人动物的方法。还提供了包含非人C5调控元件控制下的人或人源化C5基因的非人动物，包括非人类动物，其以内源性的人C5编码序列替代人C5编码序列非人C5位点。还提供了包含非人C3调控元件控制下的人或人源化C3基因的非人动物，包括用人或人源化C3蛋白编码替代非人C3蛋白编码序列的非人动物在内源性非人C3位点的序列。提供包含人或人源化C3和/或C5序列的非人动物，其中非人类动物是啮齿动物，例如小鼠或大鼠。

15. 发明授权

US11845989B2 Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors 有权
公开(公告)号：US11845989B2
公开(公告)日：2023-12-19
申请号：US17031523
申请日：2020-09-24
申请人： Regeneron Pharmaceuticals, Inc.
发明人： Kavita Praveen , Claudia Schurmann , Lauren Gurski , Tanya Teslovich Dostal , Goncalo Abecasis , Aris Baras , Giovanni Coppola , Gaurang Patel , Ying Hu , Carmelo Romano , Giusy Della Gatta , Trikaldarshi Persaud
IPC分类号： C07H21/02 , C07H21/04 , C12Q1/6883 , A61P27/02 , C12N15/10 , C12N15/11 , A61K31/713 , C12N15/113
CPC分类号： C12Q1/6883 , A61K31/713 , A61P27/02 , C12N15/1096 , C12N15/111 , C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2310/531 , C12N2320/30 , C12Q2600/106 , C12Q2600/156
摘要： The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.

16. 发明授权

US11479602B2 Methods of treating C5-associated diseases comprising administering anti-C5 antibodies 有权
公开(公告)号：US11479602B2
公开(公告)日：2022-10-25
申请号：US16819989
申请日：2020-03-16
申请人： Regeneron Pharmaceuticals, Inc.
发明人： Ying Hu , Adrianna Latuszek , Carmelo Romano , William Olson
IPC分类号： A61K39/395 , C07K16/18 , A61K45/06 , A61K39/00
摘要： The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.

17. 发明授权

US09795121B2 Humanized C3 animals 有权
公开(公告)号：US09795121B2
公开(公告)日：2017-10-24
申请号：US14703818
申请日：2015-05-04
申请人： Regeneron Pharmaceuticals, Inc.
发明人： Ying Hu , Adrianna Latuszek , Jingtai Cao , Alexander Mujica , Stanley Wiegand , John McWhirter , Andrew Murphy , Lynn Macdonald
IPC分类号： A01K67/027 , A61K49/00 , C07K14/47
CPC分类号： A01K67/0278 , A01K2207/15 , A01K2217/072 , A01K2227/105 , A01K2267/03 , A01K2267/0368 , A61K49/0008 , C07K14/472
摘要： Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus. Non-human animals comprising human or humanized C3 and/or C5 sequences, wherein the non-human animals are rodents, e.g., mice or rats, are provided.

18. 发明授权

US12037401B2 Anti-TrkB monoclonal antibodies and methods of use 有权
公开(公告)号：US12037401B2
公开(公告)日：2024-07-16
申请号：US17342749
申请日：2021-06-09
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： Susan Croll , Min Gao , Ying Hu
IPC分类号： C07K16/28 , A61K9/00 , A61K39/00 , A61P25/00
CPC分类号： C07K16/2863 , A61K9/0019 , A61P25/00 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides antibodies that bind specifically to TrkB and methods of using the same. According to certain embodiments, the antibodies of the invention are agonist antibodies that are neuroprotective, as shown by their effect on enhancing the survival of retinal ganglion cells in vitro. As such, these agonist antibodies may be used to treat diseases or disorders of the eye, such as, but not limited to glaucoma. In addition, other neuronal diseases or disorders may benefit from treatment with these agonist antibodies, including any disease or disorder characterized in part by neuronal damage. In certain embodiments, the invention includes antibodies that bind TrkB and mediate cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies.

19. 发明公开

US20230174631A1 ANTI-C5 ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：US20230174631A1
公开(公告)日：2023-06-08
申请号：US17933148
申请日：2022-09-19
申请人： Regeneron Pharmaceuticals, Inc.
发明人： Ying Hu , Adrianna Latuszek , Carmelo Romano , William Olson
IPC分类号： C07K16/18 , A61K39/395 , A61K45/06
CPC分类号： C07K16/18 , A61K39/3955 , A61K45/06 , A61K2039/505
摘要： The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.

20. 发明申请

US20220370489A1 Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors 有权
公开(公告)号：US20220370489A1
公开(公告)日：2022-11-24
申请号：US17678792
申请日：2022-02-23
申请人： Regeneron Pharmaceuticals, Inc.
发明人： Gaurang Patel , Ying Hu , Kavita Praveen , Giovanni Coppola , Goncalo Abecasis , Aris Baras , Carmelo Romano
IPC分类号： A61K31/713 , A61K45/06 , C12Q1/6883 , A61P27/06
摘要： The present disclosure provides methods of treating subjects having inflammation with an Angiopoietin-Like 7 (ANGPTL7) inhibitor and a glucocorticoid, methods of decreasing glucocorticoid-induced ophthalmic conditions in subjects, and methods of identifying subjects having an increased risk of developing glucocorticoid-induced ophthalmic conditions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式